[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628307":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":26,"responsibleParty":37,"collaborators":26,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":43,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":26,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":68,"whyStopped":26,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":26},{"fullName":5,"class":6},"Jinnah Postgraduate Medical Centre","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Topical Methotrexate 1% Gel","EXPERIMENTAL","Participants in this arm will receive topical methotrexate 1% gel applied to affected scalp areas twice daily for 24 weeks. Treatment response will be assessed using the Severity of Alopecia Tool (SALT) score at baseline and during follow-up visits at weeks 4, 12, and 24.",[13],"Drug: Methotrexate 1% Topical Gel",{"label":15,"type":16,"description":17,"interventionNames":18},"Topical Minoxidil 5% Spray","ACTIVE_COMPARATOR","Participants in this arm will receive topical minoxidil 5% spray applied to affected scalp areas twice daily for 24 weeks. Treatment response will be assessed using the Severity of Alopecia Tool (SALT) score at baseline and during follow-up visits at weeks 4, 12, and 24.",[19],"Drug: Minoxidil 5% Topical Spray",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Methotrexate 1% Topical Gel","Topical methotrexate 1% gel will be applied to the affected areas of the scalp twice daily for a duration of 24 weeks. Methotrexate acts as an immunomodulatory agent that suppresses autoimmune inflammation directed against hair follicles in alopecia areata.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Minoxidil 5% Topical Spray","Minoxidil 5% spray will be applied to the affected areas of the scalp twice daily for 24 weeks. Minoxidil promotes hair regrowth by enhancing follicular blood flow, prolonging the anagen phase of the hair cycle, and stimulating hair follicle activity.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Nimra Khan PGR, FCPS","CONTACT","+92 347 2454728","drndkhan458@gmail.com",{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Nimra Khan","PGR","100628307","phase-4-topical-methotrexate-vs-minoxidil-for-localized-alopecia-areata-100628307",false,"NCT07459933","Topical Methotrexate vs Minoxidil for Localized Alopecia Areata","Comparative Study Between Topical Methotrexate 1% Gel and Minoxidil 5% Spray in the Treatment of Localized Alopecia Areata: A Randomized Controlled Trial","MTX-MNX-AA","Inclusion Criteria:\n\nPatients aged 18 to 50 years.\n\nPatients of either gender.\n\n* Patients diagnosed with localized alopecia areata, defined as one or more smooth, well-circumscribed patches of non-scarring hair loss on the scalp with less than 25% scalp involvement, assessed using the Severity of Alopecia Tool (SALT) score.\n* Patients not previously treated with topical methotrexate or minoxidil for alopecia areata.\n* Patients willing to provide written informed consent and comply with follow-up visits.\n\nExclusion Criteria:\n\n* Patients with other types of alopecia, including androgenetic alopecia, telogen effluvium, or scarring alopecia.\n* Patients with systemic diseases that may influence hair growth or treatment response, such as uncontrolled thyroid disease, uncontrolled diabetes mellitus, or autoimmune connective tissue disorders.\n* Pregnant or lactating women.\n* Patients who have used topical or systemic treatment for alopecia areata within the past 3 months.\n* Patients with known hypersensitivity or allergy to methotrexate or minoxidil.","ALL","18 Years","50 Years",{"count":53,"type":54},268,"ESTIMATED","INTERVENTIONAL",[57],"PHASE4","Alopecia areata is an autoimmune disorder characterized by well-defined, non-scarring patches of hair loss on the scalp and other hair-bearing areas. Although several treatment options are available, there is no universally accepted standard therapy, and treatment responses vary widely among patients.\n\nMinoxidil is commonly used for hair regrowth due to its ability to stimulate hair follicles and prolong the anagen phase of the hair cycle. Methotrexate, an immunosuppressive agent traditionally used in inflammatory and autoimmune diseases, has also been explored as a potential treatment for alopecia areata because of its ability to suppress immune-mediated follicular damage.\n\nThis randomized controlled trial aims to compare the efficacy and safety of topical methotrexate 1% gel versus minoxidil 5% spray in patients with localized alopecia areata. Eligible participants will be randomly assigned to receive either topical methotrexate gel or minoxidil spray and will be followed for 24 weeks. Treatment response will be assessed using the Severity of Alopecia Tool (SALT) score. The findings of this study may help identify an effective therapeutic option for patients with localized alopecia areata and contribute to improving clinical management strategies for this condition.",[60],"Alopecia Areata",[62,63,64,65,66,67],"Localized Alopecia Areata","Topical Methotrexate","Minoxidil 5%","Hair Regrowth","Autoimmune Hair Loss","SALT Score","NOT_YET_RECRUITING","2026-03-04",{"date":71,"type":72},"2026-03-10","ACTUAL",{"date":74,"type":54},"2026-03-15",{"date":76,"type":54},"2026-09-15",{"name":5,"class":6}]